首页> 美国卫生研究院文献>British Heart Journal >Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor?
【2h】

Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor?

机译:急性心肌梗塞溶栓治疗后糖尿病患者再灌注受损的酶学证据:纤溶酶原激活物抑制剂的作用?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVE--To compare the activity of plasminogen activator inhibitor (PAI-1) in diabetic and non-diabetic patients admitted with acute myocardial infarction and to determine whether PAI-1 activity influences reperfusion after thrombolytic therapy. DESIGN--Prospective study of patients admitted with acute myocardial infarction. SETTING--District general hospital. MAIN OUTCOME MEASURES--Reperfusion assessed by time to peak release of creatine kinase-MB isoenzyme. RESULTS--Baseline PAI-1 activity and antigen concentrations were significantly higher in diabetic patients (n = 45) than in non-diabetic patients (n = 110) (24.6 (6.9) v 18.6 (7.9) AU/ml (AU = arbitrary units) (p = 0.0001) and 58.8 (13.1-328.8) v 41.0 (10.9-125.4) ng/ml (p = 0.004). Time to peak release of creatine kinase-MB was calculated in 123 (80%) patients. In 98 who received thrombolytic therapy the median time to peak enzyme release was 15.5 h (7.5-24 h) in diabetic patients (n = 26) and 12 h (5-26 h) in non-diabetic patients (n = 72) (p = 0.005). In those with a time to peak release of < or = 12 h, indicating likely successful reperfusion, PAI-1 activity was 17.5 (7.8) AU/ml compared with 22.8 (7.7) AU/ml in those with a time to peak release of > 12 h (p = 0.001). In multiple regression analysis both diabetes (p = 0.0001) and PAI-1 activity at admission (p = 0.029) were independently related to successful reperfusion. In 13 patients with evidence of reinfarction in hospital PAI-1 activity on day 3 was 26.7 (6.4) AU/ml compared with 21.7 (6.3) AU/ml in those without evidence of reinfarction (p = 0.032). CONCLUSION--Both raised PAI-1 activity on admission and diabetes were associated with a reduced likelihood of enzymatic evidence of reperfusion after thrombolytic therapy. Increased PAI-1 activity on day 3 was associated with an increased risk of reinfarction. Diabetic patients had higher PAI-1 activity on admission. This may partly explain their reduced likelihood of reperfusion.
机译:目的-比较纤溶酶原激活剂抑制剂(PAI-1)在糖尿病和非糖尿病急性心肌梗死患者中的活性,并确定PAI-1活性是否影响溶栓治疗后的再灌注。设计-对急性心肌梗死患者的前瞻性研究。地点-地区综合医院。主要观察指标-通过肌酸激酶-MB同工酶峰值释放的时间评估再灌注。结果-糖尿病患者(n = 45)的基线PAI-1活性和抗原浓度显着高于非糖尿病患者(n = 110)(24.6(6.9)v 18.6(7.9)AU / ml(AU =任意单位(p = 0.0001)和58.8(13.1-328.8)v 41.0(10.9-125.4)ng / ml(p = 0.004)。计算了123(80%)患者的肌酸激酶-MB峰值释放时间。 98位接受溶栓治疗的患者中,达到峰值酶释放的中位时间在糖尿病患者(n = 26)为15.5 h(7.5-24 h),在非糖尿病患者(n = 72)为12 h(5-26 h)(p = 0.005)。在达到峰值释放时间<或= 12 h的患者中,表明可能成功再灌注,PAI-1活性为17.5(7.8)AU / ml,而在一段时间内为22.8(7.7)AU / ml至峰值释放> 12 h(p = 0.001)。在多元回归分析中,糖尿病(p = 0.0001)和入院时PAI-1活性(p = 0.029)与成功的再灌注独立相关;在13例有再梗塞迹象的患者中在医院PAI中第3天的-1活性为26.7(6.4)AU / ml,而没有再梗塞迹象的患者的活性为21.7(6.3)AU / ml(p = 0.032)。结论-入院和糖尿病时PAI-1活性均升高与溶栓治疗后酶学证据再灌注的可能性降低相关。第3天PAI-1活性增加与再梗塞风险增加有关。糖尿病患者入院时PAI-1活性较高。这可以部分解释其降低的再灌注可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号